Corvus Pharmaceuticals, Inc.

DB:C17 Stock Report

Market Cap: €537.0m

Corvus Pharmaceuticals Valuation

Is C17 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of C17 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate C17's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate C17's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for C17?

Key metric: As C17 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for C17. This is calculated by dividing C17's market cap by their current book value.
What is C17's PB Ratio?
PB Ratio45.1x
BookUS$12.41m
Market CapUS$559.21m

Price to Book Ratio vs Peers

How does C17's PB Ratio compare to its peers?

The above table shows the PB ratio for C17 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
FYB Formycon
1.4x31.5%€827.2m
BIO3 Biotest
2.1x82.7%€1.4b
HPHA Heidelberg Pharma
2.9x-33.0%€103.9m
2INV 2invest
1xn/a€63.8m
C17 Corvus Pharmaceuticals
45.1x12.1%€559.2m

Price-To-Book vs Peers: C17 is expensive based on its Price-To-Book Ratio (45.1x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does C17's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
C17 45.1xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: C17 is expensive based on its Price-To-Book Ratio (45.1x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is C17's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

C17 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio45.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate C17's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst C17 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€8.67
€14.92
+72.0%
30.6%€22.73€11.36n/a4
Nov ’25€8.08
€11.35
+40.4%
43.3%€19.45€7.41n/a4
Oct ’25€4.68
€9.10
+94.6%
64.6%€18.87€3.15n/a4
Sep ’25€3.69
€7.21
+95.6%
38.2%€10.99€3.20n/a4
Aug ’25€2.32
€7.23
+211.8%
44.3%€11.08€3.23n/a3
Jul ’25€1.71
€7.29
+325.3%
44.3%€11.17€3.26n/a3
Jun ’25€1.89
€7.29
+285.7%
44.3%€11.17€3.26n/a3
May ’25€1.42
€6.92
+388.7%
46.5%€11.07€3.23n/a3
Apr ’25€1.65
€6.92
+319.4%
46.5%€11.07€3.23n/a3
Mar ’25€2.02
€6.39
+216.2%
50.0%€11.15€3.25n/a4
Feb ’25€1.80
€6.39
+254.8%
50.0%€11.15€3.25n/a4
Jan ’25€1.52
€6.39
+320.2%
50.0%€11.15€3.25n/a4
Dec ’24€1.35
€6.64
+391.7%
43.7%€11.22€3.27n/a5
Nov ’24€1.09
€6.64
+509.0%
43.7%€11.22€3.27€8.085
Oct ’24€1.29
€6.64
+414.6%
43.7%€11.22€3.27€4.685
Sep ’24€1.89
€6.35
+235.8%
44.5%€11.04€3.22€3.695
Aug ’24€1.98
€6.25
+215.7%
50.0%€10.91€3.18€2.324
Jul ’24€2.02
€5.94
+194.2%
42.7%€9.32€3.26€1.714
Jun ’24€2.82
€5.94
+110.7%
42.7%€9.32€3.26€1.894
May ’24€0.98
€2.61
+166.7%
22.0%€3.23€1.85€1.423
Apr ’24€0.79
€2.61
+231.4%
22.0%€3.23€1.85€1.653
Mar ’24€0.67
€2.65
+297.8%
22.0%€3.28€1.87€2.023
Feb ’24€0.74
€2.65
+259.4%
22.0%€3.28€1.87€1.803
Jan ’24€0.72
€2.65
+269.9%
22.0%€3.28€1.87€1.523
Dec ’23€0.86
€2.48
+188.0%
28.3%€3.47€1.99€1.353
Nov ’23€0.86
€3.98
+365.1%
36.9%€6.16€2.05€1.094

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$80.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$705.00

7D

-7.1%

1Y

-3.8%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.60

7D

-6.2%

1Y

90.0%

Merck

US$246.5b

Operates as a healthcare company worldwide.

6MK

US$93.40

7D

0.3%

1Y

-0.4%